Vaxcyte Reports $284.3 Million Net Loss in Q2 2026, Driven by Increased R&D Expenses

Vaxcyte, Inc. reported significant financial results for the second quarter of 2026, with a net loss of $284.3 million, compared to a net loss of $166.6 million for the same period in 2025, marking a 70.7% increase. For the six months ended June 30, 2026, the net loss was $604.9 million, nearly double the $307.3 million loss reported in the prior year. The company's total operating expenses for the second quarter reached $302.8 million, a 33.8% increase from $226.2 million in the previous year, driven primarily by a 37.9% rise in research and development costs, which totaled $267.9 million.

The increase in operating expenses was largely attributed to heightened activities related to clinical trials and product manufacturing, particularly for Vaxcyte's pneumococcal conjugate vaccine (PCV) programs. External costs associated with product manufacturing surged by 25.5% to $114.0 million, while clinical trial-related expenses skyrocketed by 143.9% to $43.1 million. The company also reported a decrease in interest income, which fell by 17.1% to $25.8 million, reflecting lower cash and investment balances and interest rates.

In terms of strategic developments, Vaxcyte has made significant progress in its clinical programs. The company has fully enrolled three ongoing Phase 3 clinical trials for its VAX-31 vaccine candidate, with a total of 6,191 adults dosed. Additionally, Vaxcyte initiated a Phase 1 study for its VAX-A1 vaccine candidate in June 2026, aimed at preventing disease caused by Group A Streptococcus. The company also announced the appointment of two new board members, enhancing its leadership team.

As of June 30, 2026, Vaxcyte's total assets amounted to $3.1 billion, up from $3.0 billion at the end of 2025. The company reported cash, cash equivalents, and investments of $2.5 billion, which it believes will be sufficient to fund operations for at least the next 12 months. Vaxcyte continues to rely on third-party manufacturers for its vaccine development and has entered into various agreements to secure manufacturing capabilities, including a significant partnership with Lonza for commercial manufacturing.

Looking ahead, Vaxcyte anticipates continued increases in research and development expenses as it advances its vaccine candidates through clinical trials and prepares for potential commercial launches. The company remains focused on securing additional funding to support its operations and development efforts, as it has yet to generate revenue from product sales. The outlook remains cautious, with the company acknowledging the inherent risks and uncertainties associated with vaccine development and the need for substantial additional capital to achieve its goals.